Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s):  AGNPF

Consumer Cyclical Healthcare Advertising Agencies Biotechnology
Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.


CSE:AGN - Post by User

Algernon Pharmaceuticals Inc.
Bullboard Posts
User Avatar Image
(4)
•••
Post by grosdavidon Apr 23, 2020 8:40pm
209 Views
Post# 30947583

As mentioned in the previous posts, NP-120 (Ifenprodil) is

As mentioned in the previous posts, NP-120 (Ifenprodil) ispotentially the best possible outcome for the COVID-19 right now...

It is not something you wish in this time of crisis, you want someone to find a drug and vaccine in order to protect the citizens. People are scared, people WILL BE scared moving forward when life will eventually have to get back to normal...

Many have failed up until now : Gilead (remdesivir), Hydroxychloroquine have failed PRELIMINARY human trials... and it is all over the news.

AGN? Human trials will eventually take place in South Korea. Some may say it is only South Korea, not Canada not USA, blabla. Why South Korea? Because Ifenprodil was initially used primarily in South Korea and Japan, therefore I believe they have more history with the drug.

I'm happy that the Phase 2 trials will take place South Korea, I feel that the country is well viewed regarding hygene/health.

I know I keep repeating, but potential investors must understand that NP-120 is a drug proven to have recognized benefits. Today's news that Remdesivir has not the positive effects wished is a good news for AGN, increasing its chance of being THE solution.

Good night,
David 

Bullboard Posts
Dealroom for high-potential pre-IPO opportunities